Press Releases
KEFEA: Vote on NHS law is important
Paves the way to improve patients’ access to innovative medicines The Cyprus Association of Research and Development Pharmaceutical Companies (KEFEA) welcomes the vote on the NHS bill by the House of Representatives Plenum. This is an important moment for the Republic...
Kyriakos Mikellis re-elected president of KEFEA
NHS and falsified medicines top priorities of new Board Kyriakos Mikellis, Cyprus Business Manager at Pfizer, has been re-elected president of the Cyprus Association of Research and Development Pharmaceutical Companies (KEFEA) for another two year term. In statements,...
Transparency in relations between pharmaceutical companies, health professionals and health organisations
KEFEA: Aim is to boost credibility at European level Transfers of value made by pharmaceutical companies involving the expenses incurred in relation to healthcare professionals and healthcare organisations are to be made public for the first time by the end of June as...
KEFEA statement on labelling of pharmaceutical products
The Cyprus Association of Research and Development Pharmaceutical Companies (KEFEA) is surprised by media reports claiming that 40% of pharmaceutical products at state pharmacies are inadequately labelled. In statements, KEFEA President Kyriacos Mikellis said that “as...
Meeting between KEFEA and the Minister of Health
The implementation of a National Health System (NHS) that will guarantee high quality healthcare services as well as other important matters involving the pharmaceutical industry were discussed during the first meeting between Health Minister George Pamborides and the...
Participating/Organising Medical Conferences/Seminars in Cyprus and Abroad subsidised by Private Companies
The Cyprus Association of Research and Development Pharmaceutical Companies (KEFEA) wishes to inform its members and the companies members of EFPIA active in Cyprus that the Health Ministry has issued a new circular dated 22 June, 2015 amending the procedures...
KEFEA: New medicine being victimised
Pharmaceutical companies say they are trapped because they cannot delete products from the price list There will be problems in the unimpeded distribution of medicines in the Cyprus market, particularly the availability of new, innovative treatments following the...
KEFEA: In danger of medicinal products being withdrawn
The Cyprus Association of Research and Development Pharmaceutical Companies (KEFEA) is concerned about the Minister of Health’s decision to proceed with a further 8.5% horizontal price cut on private sector medicines. This latest, one-sided measure may create problems...
An NHS with free choice of pharmaceuticals
Interview with KEFEA President, Kyriakos Mikellis, published in Politis newspaper Read the interview here 20150222KEFEA President...
Potential for investment in the pharmaceutical industry
Join initiatives by CIPA – KEFEA The potential to attract investments in the pharmaceutical industry and develop joint initiatives to improve the investment climate were discussed during a meeting between the Cyprus Investment Promotion Agency (CIPA) and the Cyprus...